Asuragen, MIND Institute Show Potential of Methylation PCR for Fragile X Testing | GenomeWeb

By Ben Butkus

Scientists from Asuragen and the University of California MIND Institute have published research demonstrating the ability of an Asuragen PCR-based assay to determine the methylation status of the FMR1 gene, a finding that the company said could improve diagnosis of FMR1-linked disorders such as fragile X syndrome.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.